MyJournals Home  

RSS FeedsCorrection to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience (Drug Safety)

 
 

8 november 2018 17:00:18

 
Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience (Drug Safety)
 




In the original publication of the article, the ALT and AST values in Fig.5a-e were capped at 10 ULN, which did not accurately reflect the narrative provided for each case. In this correction, the original Fig.5a-e (Fig.1a-e) and the correct Fig.5a-5e (Fig.2a-e) are published.


Del.icio.us Digg Facebook Google StumbleUpon Twitter
 
133 viewsCategory: Pharmacology
 
Mitochondria as a therapeutic target for common pathologies (Nature Reviews Drug Discovery)
Comment on `Proton Pump Inhibitor Use and Risk of Developing Alzheimer`s Disease or Vascular Dementia: A Case-Control Analysis` (Drug Safety)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Pharmacology

Use these buttons to bookmark us:
Del.icio.us Digg Facebook Google StumbleUpon Twitter


Valid HTML 4.01 Transitional
Copyright © 2008 - 2018 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn